FIELD: oncology; experimental oncology.
SUBSTANCE: invention relates to oncology, specifically to experimental oncology, and can be used to induce extracranial diffuse tumor growth in the organs of experimental animals. For this purpose inject mitochondria isolated from human glioblastoma once into male Balb/c Nude mice intraperitoneally at the rate of 3 mg of protein per 1 animal in 0.4 ml of normal saline.
EFFECT: invention allows to understand the pathogenesis of malignant growth of human glioblastoma.
1 cl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INDUCING GROWTH OF HUMAN COLON ADENOCARCINOMA IN ORGANS OF EXPERIMENTAL ANIMALS | 2023 |
|
RU2799251C1 |
| METHOD OF THE MELANOMA TUMOR NODES FORMATION IN THE BODY OF EXPERIMENTAL ANIMALS | 2022 |
|
RU2796892C1 |
| METHOD OF FORMATION OF TUMOR GROWTH IN LUNGS OF EXPERIMENTAL ANIMALS | 2023 |
|
RU2810431C1 |
| METHOD FOR OBTAINING AN ORTHOTOPIC PDX MODEL OF HUMAN BRAIN GLIOBLASTOMA ON IMMUNODEFICIENT MICE FOR PRECLINICAL STUDY OF ANTITUMOR EFFECTS OF CYTOSTATIC DRUGS | 2021 |
|
RU2761892C1 |
| METHOD FOR EXPERIMENTAL BIOTHERAPY OF B16/F10 MELANOMA | 2022 |
|
RU2779698C1 |
| METHOD OF ORTHOTOPIC HUMAN CEREBRAL GLIOBLASTOMA TRANSPLANTATION INTO CEREBRAL CORTEX PARIETALIS REGION OF IMMUNODEFICIENT MICE | 2020 |
|
RU2742449C1 |
| METHOD FOR ENHANCING THE GROWTH OF B16/F10 MELANOMA VERSUS THE GROWTH OF B16/F10 MELANOMA WITH SELF-GRAFTING AND SLOWING THE GROWTH OF LLC (LEWIS CARCINOMA) VERSUS THE GROWTH OF LLC WITH SELF-GRAFTING IN CASE OF MULTIPLE PRIMARY MALIGNANT TUMORS AGAINST THE BACKGROUND OF PRIMARY IMMUNODEFICIENCY | 2021 |
|
RU2759487C1 |
| METHOD FOR PREVENTING THE DEVELOPMENT OF MYOCARDIAL INFARCTION IN MICE WITH MELANOMA THAT DEVELOPED AGAINST THE BACKGROUND OF CHRONIC NEUROGENIC PAIN | 2022 |
|
RU2786322C1 |
| RECOMBINANT VARIOLOVACCINE VIRUS STRAIN VV-NS1-dGF PRODUCING NS1 PARVOVIRUS H-1 PROTEIN AND HAVING ONCOLYTIC ACTIVITY ON HUMAN GLIOBLASTOMA | 2018 |
|
RU2692628C1 |
| METHOD FOR CREATING POLYNEOPLASIA WITH STIMULATION OF TUMOR GROWTH IN CONDITIONS OF PRIMARY IMMUNODEFICIENCY IN EXPERIMENT | 2021 |
|
RU2751930C1 |
